ONCOCYTE CORP (OCX)
US68235C2061 - Common Stock
Overall OCX gets a fundamental rating of 2 out of 10. We evaluated OCX against 574 industry peers in the Biotechnology industry. Both the profitability and financial health of OCX have multiple concerns. OCX is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year OCX has reported negative net income.
OCX had a negative operating cash flow in the past year.
OCX had negative earnings in each of the past 5 years.
OCX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of OCX (-49.26%) is comparable to the rest of the industry.
With a Return On Equity value of -162.12%, OCX is not doing good in the industry: 65.67% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.26% | ||
| ROE | -162.12% | ||
| ROIC | N/A |
ROA(3y)-50.62%
ROA(5y)-52.42%
ROE(3y)-131.98%
ROE(5y)-111.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of OCX (8.30%) is better than 74.65% of its industry peers.
OCX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.3% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
OCX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCX has been increased compared to 1 year ago.
The number of shares outstanding for OCX has been increased compared to 5 years ago.
OCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
OCX has an Altman-Z score of -6.69. This is a bad value and indicates that OCX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -6.69, OCX is not doing good in the industry: 69.72% of the companies in the same industry are doing better.
OCX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, OCX is in line with its industry, outperforming 44.72% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.69 |
ROIC/WACCN/A
WACC10.31%
2.3 Liquidity
A Current Ratio of 1.38 indicates that OCX should not have too much problems paying its short term obligations.
OCX's Current ratio of 1.38 is on the low side compared to the rest of the industry. OCX is outperformed by 83.10% of its industry peers.
OCX has a Quick Ratio of 1.38. This is a normal value and indicates that OCX is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.38, OCX is doing worse than 82.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 56.96% over the past year.
The Revenue has decreased by -6.91% in the past year.
Measured over the past years, OCX shows a small growth in Revenue. The Revenue has been growing by 7.20% on average per year.
EPS 1Y (TTM)56.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%66.36%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y7.2%
Revenue growth 5YN/A
Sales Q2Q%-77.54%
3.2 Future
Based on estimates for the next years, OCX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.16% on average per year.
The Revenue is expected to grow by 82.53% on average over the next years. This is a very strong growth
EPS Next Y22.58%
EPS Next 2Y17.54%
EPS Next 3Y16.16%
EPS Next 5YN/A
Revenue Next Year-43.39%
Revenue Next 2Y19.01%
Revenue Next 3Y82.53%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
OCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
OCX's earnings are expected to grow with 16.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.54%
EPS Next 3Y16.16%
5. Dividend
5.1 Amount
OCX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ONCOCYTE CORP
NASDAQ:OCX (9/6/2024, 8:00:02 PM)
After market: 2.89 -0.3 (-9.4%)3.19
+0.14 (+4.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap42.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -49.26% | ||
| ROE | -162.12% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 8.3% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.38 | ||
| Quick Ratio | 1.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)56.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y22.58%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y7.2%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y